The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

OBJECTIVE: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve albuminuria in patients with high cardiorenal risk. We report albuminuria change in the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) cardiovascular outcome trial, which included populations with lower cardiorena...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosenzon, Ofri, Wiviott, Stephen D., Heerspink, Hiddo J.L., Dwyer, Jamie P., Cahn, Avivit, Goodrich, Erica L., Rozenberg, Aliza, Schechter, Meir, Yanuv, Ilan, Murphy, Sabina A., Zelniker, Thomas A., Gause-Nilsson, Ingrid A.M., Langkilde, Anna Maria, Fredriksson, Martin, Johansson, Peter A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Sabatine, Marc S., Raz, Itamar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385472/
https://www.ncbi.nlm.nih.gov/pubmed/34233928
http://dx.doi.org/10.2337/dc21-0076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385472/
https://www.ncbi.nlm.nih.gov/pubmed/34233928
http://dx.doi.org/10.2337/dc21-0076

Ejemplares similares